4551 — Torii Pharmaceutical Co Share News
0.000.00%
Last trade - 00:00- ¥178bn
- ¥144bn
- ¥60bn
BioCryst: Rises as Japan approves co's genetic disorder drug
Table: Torii Pharmaceutical - 9-MTH parent results
Table: Torii Pharmaceutical - 6-MTH parent results
Table: Torii Pharmaceutical - Q1 parent results
Table: Torii Pharmaceutical -2019 parent results
BioCryst: Jumps after submitting Japanese marketing application for swelling treatment
Table: Torii Pharmaceutical -2019 parent forecast
Brief: BioCryst Announces Partnership With Torii Pharmaceutical to Commercialize BCX7353 in Japan for the Prevention of HAE Attacks
Table: Torii Pharmaceutical - 9-MTH parent results
Table: Torii Pharmaceutical -2019 parent forecast
Brief: Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1
Table: Torii Pharmaceutical -2019 parent forecast
Table: Torii Pharmaceutical - 6-MTH parent results
Brief: Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan
Table: Torii Pharmaceutical - Q1 parent results
Brief: Torii Pharmaceutical Co Goichi Matsuda To Be President Effective March 26
Table: Torii Pharmaceutical -2018 parent results
Brief: Japan Tobacco Agrees Jan 1 To Be Termination Date Of Licensing Agreements On Six Anti-Hiv Drugs
Brief: Japan Tobacco Terminates Agreements On Exclusive Rights To Develop, Commercialize And Market Six Anti-HIV Drugs In Japan